The UK and US have secured a major commercial pact that will preserve no tariffs on British drug products being sold in the US market.
Agreement Details of the Accord
As part of the deal, the UK has pledged to boost expenditure on medicines through the public health system. This pledge guarantees that duties on these key goods will be held at nothing for a duration of three years.
This deal is in response to previous threats to significantly raise import taxes on patented drug products, with potential rates mentioned up to double the cost.
"This arrangement between the UK bolsters the worldwide climate for innovative medicines and establishes much-needed fairness to American-British pharmaceutical trade," an announcement noted.
Economic Significance
Pharmaceuticals represent one of the UK's biggest goods shipped to the America, which is easily the primary buyer for leading UK drugmakers.
Statistics show that in the year leading up to the third quarter, the UK exported pharmaceutical products valued at £11.1bn to the US. This value made up 17.4% of British export trade in that period.
"This deal secures jobs, increases investment and facilitates the UK to become a worldwide center for life sciences," the Business and Trade Secretary remarked.
Specific British Pledges
The agreement entails several specific commitments from the UK:
- Price Threshold Increase: The UK will increase the cost ceiling at which it considers new therapies to be too expensive by a quarter.
- Higher Drug Budget: There is a target to raise overall public funding on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Rebate Cap: The amount manufacturers must pay back to the NHS to prevent overspending will be restricted at 15%. Previously, rebates exceeded twenty percent.
Broader Context
The pact follows a ongoing tension between the sector and the British authorities over drug pricing and approval rates.
This friction were heightened by arguments that American consumers were charged several times more for the same drugs than consumers in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been halted or cancelled, while major expansions have been announced toward US facilities.
The Science Minister acknowledged that the NHS had to spend more on drugs, noting that its budget allocation on drugs had declined as a percentage of its total funding over the last ten years.
